Biosimilar Antibodies

Ixekizumab (LY2439821) is a humanized IgG4 monoclonal antibody engineered to selectively bind and neutralize interleukin-17A (IL-17A) with a dissociation constant (K_D) of less than 3 pM. This antibody effectively inhibits the interaction of IL-17A with its receptor, IL-17RA, without interacting with other members of the IL-17 cytokine family. Ixekizumab is primarily utilized in research focused on the pathophysiology and treatment of moderate-to-severe plaque psoriasis.

Daxdilimab is a monoclonal antibody that targets ILT7, a cell surface molecule uniquely expressed on plasmacytoid dendritic cells (pDCs). This antibody has been specifically developed for research purposes, particularly to investigate its therapeutic potential in managing acute lung injury (ALI) associated with COVID-19 infection. Daxdilimab offers a promising tool for elucidating the role of pDCs in viral infections and inflammatory responses.

Rivabazumab pegol is a pegylated Fab monoclonal antibody targeting the PcrV protein of Pseudomonas aeruginosa. This antibody is specifically designed for the investigation of chronic infections caused by Pseudomonas aeruginosa, offering a valuable tool for research in microbial pathogenesis and host-pathogen interactions during the persistent phases of this infection. Rivabazumab pegol's unique structure and specificity make it ideal for studies focused on the development and evaluation of therapeutic strategies against this challenging bacterial pathogen.

Ntx1088 is a first-in-class, potent monoclonal antibody that targets the poliovirus receptor, also known as CD155. This antibody has demonstrated potential therapeutic applications in the treatment of patients with locally advanced and metastatic solid tumors. Its specific interaction with CD155 makes it a valuable tool for research and potential clinical use in oncology.

Ginisortamab (UCB6114) is a fully human IgG4P monoclonal antibody targeting Gremlin-1. It demonstrates potent inhibitory activity with mean IC50 values of 8.2 nM and 9 nM against human and mouse Gremlin-1, respectively. By antagonizing Gremlin-1, Ginisortamab effectively disrupts the BMP signaling pathways, which are crucial in various biological processes including tissue growth and repair. This antibody holds significant potential for use in research focused on gastrointestinal (GI) tumors, providing a valuable tool for elucidating the role of Gremlin-1 in cancer pathogenesis and therapy.

Bezetabart is a human IgG1 κ monoclonal antibody targeting CD74. For accurate experimental controls, it is recommended to use Human IgG1 kappa as an isotype control.

Lofacimig is a bispecific antibody designed as a VH-VH-G1(h-CH2-CH3) dimer, specifically targeting FXI and PTA. This configuration enhances its specificity and efficacy in engaging these particular antigens, making it a valuable tool for research into coagulation and anticoagulation pathways.

ANX005 is a recombinant antibody specifically targeting C1q, the initiating molecule of the classical complement cascade. By inhibiting C1q, ANX005 is instrumental in the study of its role in autoimmune and neurodegenerative diseases. This antibody serves as a crucial tool for researchers investigating the mechanisms of immune response and disease progression in these conditions.

Anti-SLAMF7 / CS1 (PDL241) is a humanized monoclonal antibody specifically targeting CD319. This antibody is recognized for its potential as a therapeutic agent in the treatment of rheumatoid arthritis, leveraging its ability to modulate immune responses associated with the disease.

Ocankitug is a humanized IgG1κ monoclonal antibody specifically targeting thymic stromal lymphopoietin (TSLP). For experimental control purposes, it is recommended to use Human IgG1 kappa as the isotype control.

Frovocimab (LY 3015014) is a humanized IgG4 monoclonal antibody designed to neutralize proprotein convertase subtilisin/kexin type 9 (PCSK9). By inhibiting the interaction between PCSK9 and the low-density lipoprotein receptor (LDLR), Frovocimab facilitates the normal proteolytic processing of PCSK9 without disrupting its binding, thereby maintaining cholesterol homeostasis. This antibody is pivotal for research focused on lipid metabolism and cardiovascular diseases, offering potential insights into the regulation of cholesterol levels and the mechanisms of atherosclerosis.

Retifanlimab is a monoclonal antibody targeting the programmed cell death protein 1 (PD-1) receptor, designed to modulate immune responses in tumor microenvironments. This antibody is particularly utilized in the study of gastroesophageal adenocarcinoma (GEA), providing a valuable tool for researchers investigating the therapeutic potential of PD-1 inhibition in this cancer type.

Oportuzumab is a humanized monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells, specifically designed to target EpCAM (epithelial cell adhesion molecule), also known as TROP1 or CD326. This antibody is comprised of a human immunoglobulin G1 (huIgG1) heavy chain and a human kappa (huκ) light chain, exhibiting a predicted molecular weight of approximately 145 kDa. For experimental control purposes, Human IgG1 kappa, Isotype Control is recommended.

Verekitug is a human IgG1 κ monoclonal antibody targeting CRLF2. For optimal experimental control, it is recommended to use Human IgG1 kappa Isotype Control.

Rimteravimab (XVR011) is a bivalent VHH-Fc antibody engineered for potent neutralization of SARS-CoV-2. This antibody exhibits broad coverage and high stability, and features silenced Fc effector functions, making it highly effective against the disease caused by SARS-CoV-2. Its design and functionality make it an essential tool for research into COVID-19 therapies and mechanisms of viral neutralization.

Ziltivekimab (COR-001) is a humanized monoclonal antibody designed to target interleukin-6 (IL-6), a cytokine known to play a critical role in systemic inflammation. This antibody has demonstrated efficacy in lowering serum C-reactive protein (CRP) levels, indicating its potent anti-inflammatory properties. Ziltivekimab is primarily utilized in research focused on chronic systemic inflammation, particularly in conditions such as chronic kidney disease (CKD) and cardiovascular diseases, including atherosclerosis. Its specific interaction with IL-6 makes it a valuable tool for studies exploring the pathophysiology and potential therapeutic interventions for these diseases.

Abelacimab (MAA868) is a fully human IgG1 monoclonal antibody engineered to bind with high affinity to the catalytic structural domain of Factor XI (FXI). This interaction effectively locks FXI in its zymogen conformation, inhibiting its activation by Factor XIIa (FXIIa) or thrombin. Due to its specific mechanism of action, Abelacimab is an excellent tool for research into thromboembolic diseases, providing insights into the regulation of coagulation pathways and the development of antithrombotic therapies.

Denrakibart is a human monoclonal antibody of the IgG2κ subtype that specifically targets CCL17. For experimental control purposes, it is recommended to use Human IgG2 kappa as the isotype control.

Namilumab (AMG203) is a human IgG1 monoclonal antibody designed to bind with high affinity to granulocyte-macrophage colony-stimulating factor (GM-CSF), effectively neutralizing its activity. This antibody is primarily utilized in research focused on understanding and treating rheumatoid arthritis, providing a valuable tool for investigating the role of GM-CSF in inflammatory processes.

Melrilimab (GSK 3772847) is a monoclonal antibody of the IgG2-kappa subclass that targets IL1RL1, also known as ST2, IL33R, DER4, and FIT-1. This antibody is specifically designed for the investigation of its role in asthma pathogenesis and potential therapeutic applications.

Drotokibart is a humanized IgG4κ monoclonal antibody that specifically targets the IL4RA protein. For experimental controls, it is recommended to use Human IgG4 (S228P) kappa as the isotype control. This specificity and control recommendation ensure precise and reliable results in research applications focusing on the IL4RA pathway.

Reozalimab is a bispecific antibody engineered to target both PD-1 and PD-L1. This unique formulation enhances the immune response against tumor cells by facilitating antibody-dependent cell-mediated cytotoxicity (ADCC). It is primarily utilized in oncological research to investigate immune checkpoint blockade therapies.

Romilkimab (SAR156597) is a chimeric humanized immunoglobulin antibody engineered to specifically target both interleukin-4 (IL-4) and interleukin-13 (IL-13). This dual specificity allows for potential therapeutic applications in treating diseases characterized by overactive IL-4 and IL-13 pathways, such as certain inflammatory and autoimmune disorders.

Apitegromab (SRK-015) is a monoclonal antibody targeting promyostatin. This biologic is specifically designed for the investigation of neuromuscular disorders, including spinal muscular atrophy. Apitegromab's mechanism involves modulating the activity of promyostatin, a key regulator in muscle development and growth, making it a valuable tool in research focused on muscle pathology and therapeutic development.

Adebrelimab (SHR-1316) is a humanized IgG4 monoclonal antibody targeting PD-L1 within the PD-1/PD-L1 pathway. Demonstrating significant antitumor activity, this antibody is particularly effective in treating solid tumors, such as extensive-stage small-cell lung cancer (SCLC). Adebrelimab's mechanism of action involves modulating the immune response by inhibiting the PD-1/PD-L1 interaction, thereby enhancing the body's antitumor immune activity. This product is pivotal for research focused on immune checkpoint pathways and cancer immunotherapy.

Birtamimab (NEOD001) is an investigational monoclonal antibody designed to specifically and selectively target and clear amyloid deposits. This antibody is primarily utilized in research focused on light chain amyloidosis, providing a targeted approach to study the pathological mechanisms and potential therapeutic interventions for this condition.

Landogrozumab (LY2495655) is a humanized monoclonal antibody targeting myostatin, a protein known to inhibit muscle growth. By neutralizing myostatin, Landogrozumab has been shown to enhance muscle volume, hand grip strength, and overall muscle function. This antibody is primarily utilized in research focused on muscle wasting diseases, providing a valuable tool for investigating potential therapeutic interventions for conditions characterized by muscle degeneration and loss.

Gontivimab (ALX-0171; VR-465) is a potent nanobody targeting the respiratory syncytial virus (RSV) prefusion F protein, exhibiting a dissociation constant (K_D) of 0.113 nM. This high-affinity binding is indicative of its robust antiviral properties. Gontivimab has demonstrated efficacy in reducing viral load in both nasal and pulmonary tissues, highlighting its potential for therapeutic applications in RSV infections.

Enristomig is a monoclonal antibody that targets TNFRSF9 and CD274, designed for precision in immunotherapy research. This antibody binds specifically to TNFRSF9, also known as CD137, and CD274, known as PD-L1, playing a crucial role in modulating immune responses. It is utilized extensively in studies focusing on cancer immunotherapy, autoimmune diseases, and immune checkpoint regulation.

Anatumomab mafenatox (ABR-214936) is a 73 kDa recombinant protein engineered to target the tumor-associated antigen 5T4, commonly expressed in various malignancies. This biologic agent is a fusion of a modified form of staphylococcal enterotoxin A (SEA) and a murine Fab fragment, designed for precise recognition and binding to the 5T4 antigen. Commonly reported adverse effects associated with Anatumomab mafenatox include fever, hypotension, pain, nausea, and drowsiness, which should be considered in therapeutic settings. This product is pivotal for research focused on the characterization and treatment of cancers expressing the 5T4 antigen.

Bertilimumab (CAT 213; iCo-008) is a human monoclonal antibody specifically designed to target eotaxin-1 (CCL11), a key chemokine involved in the recruitment of eosinophils to inflammatory sites. This antibody has significant potential for the study of allergic disorders, offering a precise tool for elucidating the role of eotaxin-1 in the pathogenesis of these conditions. Bertilimumab may facilitate the development of therapeutic strategies aimed at modulating immune responses in allergic diseases.

PF-03732010 is a humanized monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells, specifically targeting CDH3/P-cadherin. This antibody is composed of a human IgG1 type heavy chain and a human lambda (huλ) type light chain, with a predicted molecular weight of 142.7 kDa. For isotype control, Human IgG1 kappa, Isotype Control is recommended. PF-03732010 is designed for precise binding to CDH3, making it an essential tool for research focused on cellular adhesion processes and cancer biology.

GFB-024 is a recombinant humanized monoclonal antibody specifically designed to target the CB1 receptor, also known as CNR1. This antibody binds with high specificity and affinity, making it an essential tool for the study of CB1 receptor functions in various physiological and pathological processes. GFB-024 is ideal for applications in both basic research and therapeutic development related to the endocannabinoid system.

Nezutatug is a monoclonal antibody targeting the human epidermal growth factor receptor 3 (HER3), a protein implicated in the modulation of cell growth and differentiation. This antibody is specifically designed for use in cancer research, where it serves as a crucial tool for studying the role of HER3 in oncogenic processes and potential therapeutic interventions. Nezutatug is suitable for various experimental applications, including flow cytometry, Western blotting, and immunohistochemistry, making it a versatile reagent in the investigation of HER3's function and its involvement in cancer pathogenesis.

Derlotuximab is a chimeric antibody of the scFv-Fc (huIgG1) type, produced in Chinese Hamster Ovary (CHO) cells, and specifically targets Histone H1. This antibody has a predicted molecular weight of 145.1 kDa. For experimental control purposes, the appropriate isotype control is Human IgG1 kappa.

Birinkibart is a human monoclonal antibody of the IgG4κ subtype, specifically targeting the CSF2RB receptor. For experimental control purposes, it is recommended to use Human IgG4 (S228P) kappa as an isotype control. This specificity and configuration make Birinkibart suitable for detailed studies on CSF2RB-related pathways and potential therapeutic applications.

Urelumab is a fully human IgG4 monoclonal antibody that functions as a CD137 agonist without binding to its natural ligand. This antibody is designed to potentiate the antitumor activities of T-cells and natural killer (NK) cells. Additionally, Urelumab has been shown to potentially enhance the cytotoxic effects of Rituximab. It is primarily utilized in research focused on various non-Hodgkin lymphomas, including diffuse large B-cell lymphoma and follicular lymphoma. This makes Urelumab a valuable tool in the study of immune-mediated cancer therapies.

Losatuxizumab is a monoclonal antibody targeting the Epidermal Growth Factor Receptor (EGFR). It exhibits high affinity for various forms of EGFR, with EC50 values of 0.96 nM for wild-type EGFR, 0.09 nM for the EGFRC271A,C283A mutant, 0.12 nM for EGFRvIII, and 0.66 nM for EGFR1-501. This antibody is specifically designed for the study of cancers expressing EGFR, making it an essential tool for research in oncology and molecular biology.

Osemitamab is a recombinant IgG1 monoclonal antibody specifically designed to target human claudin-18.2. This antibody is comprised of a human-Mus musculus monoclonal TST001 gamma 1-chain linked via disulfide bonds to a human-Mus musculus monoclonal TST001 kappa-chain, forming a dimeric structure. When used in conjunction with Capecitabine and Oxaliplatin, Osemitamab serves as a potent investigational tool for the study of gastric (G) and gastroesophageal junction (GEJ) cancers. This specificity and application make it a valuable asset for targeted cancer therapy research.

Anti-CEACAM7 Antibody (P3-7B) is a chimeric mouse monoclonal antibody of the IgG1, κ subclass, specifically designed to target human Carcinoembryonic Antigen-Related Cell Adhesion Molecule 7 (CEACAM7). This antibody has been developed for high specificity and affinity in recognizing the CEACAM7 antigen, making it ideal for detailed studies in cancer biology and immunology. For accurate experimental control, it is recommended to use Mouse IgG1 kappa, Isotype Control as the isotype control.

Tobevibart (VIR-3434) is a human IgG1 lambda monoclonal antibody specifically targeting the hepatitis B virus (HBV) surface antigen (HBsAg). Demonstrating potent in vitro neutralization capabilities, Tobevibart effectively inhibits HBsAg across all HBV genotypes and blocks viral entry for both HBV and the hepatitis delta virus (HDV). For experimental control purposes, the use of Human IgG1 lambda1 Isotype Control is recommended.

Lunlekitug is a human monoclonal antibody of the IgG1κ subtype that specifically targets interleukin-1 alpha (IL1A). For experimental control purposes, it is recommended to use Human IgG1 kappa as an isotype control. This antibody is designed for use in research studies examining the role and modulation of IL1A in various biological processes and disease states.

The Anti-CXCL8/IL-8 Antibody is a human monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells, specifically targeting the CXCL8/IL-8 chemokine. This antibody is structured with a human IgG1 heavy chain and a human kappa light chain, exhibiting a predicted molecular weight of 145 kDa. For experimental control purposes, the Human IgG1 kappa, Isotype Control serves as the appropriate isotype control for this antibody. This product is essential for research focused on inflammatory responses and chemotactic processes involving CXCL8/IL-8.

Tuparstobart (Incagn-02385) is an IgG1κ monoclonal antibody designed to specifically target LAG-3, an immune checkpoint receptor. LAG-3 is predominantly expressed on activated T cells, NK cells, B cells, and plasmacytoid dendritic cells. This antibody is engineered to bind to LAG-3, thereby modulating immune responses, which may be critical in the research of immune regulation and potential therapeutic applications in immune-related disorders.

Nelistotug (GSK 6097608; GSK6097608) is a human IgG1κ monoclonal antibody that specifically targets CD96. This antibody is designed for the precise identification and study of CD96 expression in various biological research applications. It is particularly useful in investigating the role of CD96 in immune response modulation and its potential implications in immunotherapy.

The Anti-CXCR4/CD184 Antibody is a recombinant human monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells. It specifically targets the CXCR4/CD184 receptor, a chemokine receptor implicated in various biological processes including cell migration, hematopoiesis, and tumor metastasis. This antibody is composed of a human IgG1 heavy chain and a human lambda light chain, and exhibits a molecular weight of approximately 145 kDa. For experimental control purposes, the Human IgG1 kappa, Isotype Control is recommended.

Trabikibart (CSL311) is a βc (CSF2RB)-specific, fully human monoclonal antibody engineered to target a unique epitope on the cytokine-binding site of the human βc receptor. Exhibiting a picomolar binding affinity, this antibody effectively binds to the receptor, demonstrating robust specificity. Trabikibart acts as a potent inhibitor of the combined biological activities of IL-3, GM-CSF, and IL-5, particularly impacting the survival of eosinophils. This characteristic positions Trabikibart as a valuable tool for investigating the mechanisms underlying chronic inflammatory diseases and exploring potential therapeutic interventions.

Clenoliximab (IDEC-151) is a chimeric monoclonal antibody derived from macaque and human sources, classified within the immunoglobulin G4 subclass. It exhibits specificity for the CD4 molecule expressed on the surface of T lymphocytes. This antibody is primarily utilized in research focused on elucidating the pathophysiology and potential therapeutic interventions for rheumatoid arthritis.

MEDI-570 is a humanized monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells, specifically targeting ICOS/CD278. This antibody is comprised of a human IgG1 heavy chain and a human kappa light chain, with an estimated molecular weight of 145 kDa. For experimental control purposes, Human IgG1 kappa, Isotype Control is recommended.